Development of pluripotent stem cell nEPS overcoming cancer, patent application in 147 countries
페이지 정보View 110 작성일 2021-01-14 16:59
Induced Pluripotent Stem Cell (iPSC), which is attracting attention as a “dream treatment”. Unlike “embryonic stem cells,” which were controversial in ethics due to Dr. Woosuk Hwang's incident in the past, iPSCs are stem cells that are produced based on adult cells. Shinya Yamanaka, a professor at Kyoto University in Japan, succeeded in creating iPSCs for the first time and received the Nobel Prize in in 2012, and various clinical results have been announced. However, the production efficiency is very low and it has the possibility of malignant tumors, so controlling it was a big task. After a long effort and sacrifice, developed nEPS (newly Elicited Pluripotent Stem Cells without side effects by natural compound).
BBHC has confirmed the possibility of nEPS as the next-generation drug after undergoing animal experiments with authorities such as Seoul National University Hospital in Bundang for the past five years, and is now preparing for overseas export of technology and clinical trials for humans.
In an interview with our magazine, the CEO of BBHC was confident that she would change the existing perception of stem cells and make a big breakthrough in the bio industry.